OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study

Autor: Carbone, D., Lee, J., Kris, M., Wistuba, I., Kwiatkowski, D., Owen, D., Bunn, P., Johnson, B., Oezkan, F., Tang, Y., Parra, E.R., Lozanski, G., Rivard, C., Schulze, K., Nicholas, A., Johnson, A., Grindheim, J., Shames, D., Phan, S., Toloza, E., Haura, E., Mcnamee, C., Gainor, J., Patterson, A., Waqar, S., Raz, D., Reckamp, K., Finley, D., Rusch, V., Chaft, J., Abel, J.
Zdroj: In Journal of Thoracic Oncology March 2021 16(3) Supplement:S115-S116
Databáze: ScienceDirect